title: Cisplatin, doxorubicin, mitomycin C, and 5-fluorouracil for the treatment of metastatic non-small cell lung cancer. Limited activity of an aggressive chemotherapy regimen.
abstract: We conducted a Phase II study to determine the efficacy of cisplatin, doxorubicin, mitomycin C, and 5-fluorouracil in patients with untreated non-small cell lung cancer. Patients were accrued through the Connecticut Oncology Association (COA), an organization composed of community and university oncologists. Thirteen COA oncologists enrolled 30 patients over 12 months and 26 were eligible for the final analysis. Patients received cisplatin 75 mg/m2, doxorubicin 30 mg/m2, mitomycin C 6.5 mg/m2, and 5-fluorouracil 750 mg/m2 on day 1. The treatment was repeated every 4 weeks, with mitomycin C given during the first 3 cycles and then every other cycle. There were 5 (19%) partial responses, lasting 1.3-7.3 months. The median time to progression was 10.3 months (0.3-12.5 months). Median survival was 7.5 months (0.3-34 months). The major toxicities were related to myelosuppression and there was one septic death. This study demonstrates the limited efficacy of an aggressive regimen using "active" agents in patients with advanced non-small cell lung cancer.
authors.affiliation: Yale University School of Medicine, Section of Medical Oncology, New Haven, CT 06510.
authors.forename: J R
authors.initials: JR
authors.lastname: Murren
authors.forename: H J
authors.initials: HJ
authors.lastname: Durivage
authors.forename: A H
authors.initials: AH
authors.lastname: Rosenberg
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: S A
authors.initials: SA
authors.lastname: Del Prete
authors.forename: G J
authors.initials: GJ
authors.lastname: Murphy
authors.forename: A C
authors.initials: AC
authors.lastname: Buzaid
authors.forename: W N
authors.initials: WN
authors.lastname: Hait
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage; D016019:Survival Analysis
chemical_list: D008937:Mitomycins; D004317:Doxorubicin; D002945:Cisplatin; D005472:Fluorouracil